蛋白酶K市场 - 全球产业规模、份额、趋势、机会及预测（按治疗领域、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球蛋白酶 K 市场预计将从 2025 年的 52.1 亿美元成长到 2031 年的 80.9 亿美元，复合年增长率为 7.61%。

作为一种稳定且广效的丝胺酸蛋白酶，蛋白酶K广泛应用于蛋白质消化以及DNA和RNA分离过程中的核酸酶灭活。市场成长的主要驱动力是感染疾病和遗传性疾病发病率的上升，这使得对可靠的分子诊断检测和基因测序的需求变得特别迫切。这种对精准临床诊断和生命科学研究的基本需求，也支撑了样品製备所需的高纯度酵素试剂的持续需求。

根据世界卫生组织（世卫组织）的数据，预计到2024年全球将新增1080万例结核病病例，这一数据凸显了扩大利用这些提取酶的快速分子诊断检测的普及范围的迫切需求。儘管成长要素强劲，但市场仍面临许多障碍，例如严格的监管标准以及分子级酵素生产高成本。这些因素可能会限制供应链的扩充性，并阻碍新兴经济体的消费者负担得起。

市场驱动因素

分子诊断和体外诊断 (IVD) 应用的成长是全球蛋白酶 K 市场的主要催化剂，这主要得益于该酵素在製备用于精确分析的临床检体中发挥的关键作用。随着实验室越来越多地采用分子工作流程来识别感染疾病病原体和基因异常，对用于核酸分离的高纯度蛋白酶 K 的需求呈指数级增长。这种酵素在高通量诊断实验室中至关重要，因为它能有效降解可能抑制扩增技术的污染蛋白。此类诊断的规模极为庞大；例如，罗氏公司于 2024 年 3 月发布的 2023 年年度报告显示，该公司将在全球范围内完成 290 亿次诊断测试，这凸显了发达经济体和新兴经济体医疗保健系统在样本处理方面对可靠试剂的巨大需求。

同时，次世代定序(NGS) 技术的快速发展正在改变市场格局，对复杂基因组应用所需的高纯度酵素提出了更高的要求。现代定序平台凭藉其更高的通量和灵敏度，需要不含核酸酶和蛋白质杂质的 DNA 模板，这提高了对蛋白酶 K 製剂的要求。该领域的创新得到了大量资本投资的支持。根据赛默飞世尔科技公司于 2024 年 4 月发布的《2023 年年度报告》，该公司已投资 13 亿美元用于研发新技术，包括生命科学领域的技术。这种投资环境正在推动先进定序仪器的应用，进而带动试剂的使用。 Illumina 公司于 2024 年 2 月发布的 2023 财年财务业绩新闻稿显示，其 NovaSeq X 仪器的出货量为 352 台，显示其定序能力显着提升。这与提取酶使用量的增加密切相关。

市场挑战

严格的监管标准和分子级酵素生产相关的高成本，对全球蛋白酶K市场的成长构成了重大障碍。生产高纯度蛋白酶K需要先进的纯化製程和严格控制的环境，以彻底去除核酸酶等污染物。这些严格的合规要求需要大量的资本投入和高昂的营运成本，直接限制了製造商高效扩展供应链的能力。因此，这些关键试剂的高昂价格阻碍了其在新兴经济体的市场渗透，而价格承受能力是获得分子诊断的关键因素。

这些製造压力带来的广泛影响已体现在近期行业绩效指标。根据欧洲化学工业理事会（Cefic）预测，到2024年，欧洲化学和生物化学製造业的运转率约为75%，这一数字受到高额监管负担和营运成本的显着限制。如此低的运转率利用率凸显了製造商在扩大生产规模的同时控制遵循成本所面临的挑战。在蛋白酶K市场，这些财务和营运方面的限制直接阻碍了该行业满足全球诊断测试材料激增需求的能力。

市场趋势

在生物製药应用中，高纯度和批次间一致性至关重要，这正推动全球市场从天然细菌萃取方法向重组生产方法发生重大转变。这种转变满足了现代基因组工作流程的严格要求，提供不含动物性污染物且比天然酵素具有更高比活性的酵素。这种向先进生物製造原材料的转变已达到工业规模，并支持符合高监管标准的供应链。根据默克集团（Merck KGaA）2025年3月发布的2024年度报告，该公司製程解决方案部门的销售额达到35亿欧元。这一数字证实了市场对生产这些重组试剂所必需的高品质生物原料的强劲需求。

同时，高通量自动化工作站的普及推动了市场对即时用型液体製剂而非传统冻干粉剂的偏好。实验室越来越多地采用自动化液体处理系统，以消除人工移液误差并加快样品处理速度，这需要稳定、即用型的酵素製剂来满足自动化工作流程的需求。生命科学公司对自动化基础设施的大量投资支撑了这一营运模式的转变。根据Tecan集团于2025年3月发布的2024年度报告，该公司生命科学部门的销售额将达到3.97亿瑞士法郎，凸显了液体处理平台的广泛应用推动了这些专用酵素製剂的消费。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球蛋白酶K市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依治疗领域（感染疾病、糖尿病、肿瘤、心臟病、肾臟病、自体免疫疾病、神经病变、其他）
  • 依应用（基因组DNA/RNA分离/纯化、原位杂合反应、粒线体分离、酵素去除）
  • 依最终使用者（合约研究组织、学术机构、生技公司、诊断检查室）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美蛋白酶K市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲蛋白酶K市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区蛋白酶K市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲蛋白酶K市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲蛋白酶K市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球蛋白酶K市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Promega Corporation
• QIAGEN NV
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd
• Worthington Biochemical Corporation
• New England Biolabs, Inc.
• BIORON GmbH
• Sisco Research Laboratories Pvt. Ltd.
• Bioline Global Pty Ltd
• Codexis, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Proteinase K Market is projected to increase from a valuation of USD 5.21 Billion in 2025 to USD 8.09 Billion by 2031, reflecting a compound annual growth rate of 7.61%. As a stable and broad-spectrum serine protease, Proteinase K is extensively applied for protein digestion and the inactivation of nucleases during the isolation of DNA and RNA. The growth of this market is primarily driven by the rising incidence of infectious diseases and genetic disorders, which creates a critical need for robust molecular diagnostic testing and genomic sequencing. This fundamental demand for accurate clinical diagnostics and life sciences research underpins the continuous requirement for high-purity enzymatic reagents necessary for sample preparation.

According to data from the World Health Organization, tuberculosis resulted in an estimated 10.8 million incident cases globally in 2024, a statistic that highlights the urgent need to expand access to molecular rapid diagnostic tests utilizing these extraction enzymes. Despite these powerful growth drivers, the market encounters significant hurdles related to rigorous regulatory standards and the high costs involved in manufacturing molecular-grade enzymes. These factors can limit the scalability of supply chains and hinder affordability within emerging economies.

Market Driver

The growth of Molecular Diagnostic and In Vitro Diagnostic (IVD) applications serves as a primary catalyst for the Global Proteinase K Market, anchored by the enzyme's essential function in preparing clinical samples for precise analysis. As laboratories increasingly implement molecular workflows to identify infectious pathogens and genetic anomalies, the demand for high-grade Proteinase K for nucleic acid isolation has risen sharply. This enzyme efficiently digests contaminating proteins that could otherwise inhibit amplification technologies, making it vital for high-throughput diagnostic facilities. The scale of this diagnostic volume is massive; for instance, Roche reported in its 'Annual Report 2023', published in March 2024, that it delivered 29 billion diagnostic tests globally, underscoring the vast quantity of reliable reagents required for sample processing across developed and emerging healthcare systems.

Concurrently, rapid advancements in Next-Generation Sequencing (NGS) technologies are transforming the market by necessitating superior enzymatic purity for complex genomic applications. Modern sequencing platforms, offering enhanced throughput and sensitivity, require DNA templates free from nuclease and protein impurities, thereby raising the standards for Proteinase K formulations. Innovation in this sector is supported by significant capital investment; according to Thermo Fisher Scientific's 'Annual Report 2023' released in April 2024, the company invested $1.3 billion in research and development to deliver new technologies, including those benefiting life sciences. This investment environment facilitates the deployment of advanced sequencing fleets that drive reagent usage, as evidenced by Illumina's February 2024 press release regarding its fiscal year 2023 results, which reported shipments of 352 NovaSeq X instruments, signaling a strong expansion in sequencing capacity that correlates with increased extraction enzyme utilization.

Market Challenge

The rigorous regulatory standards and elevated costs associated with manufacturing molecular-grade enzymes represent a major impediment to the growth of the Global Proteinase K Market. Producing high-purity Proteinase K demands advanced purification processes and strictly controlled environments to guarantee the complete absence of contaminants such as nucleases. These strict compliance requirements necessitate substantial capital investment and high operational expenditures, which directly restrict the ability of manufacturers to efficiently scale supply chains. Consequently, the high price point of these essential reagents limits market penetration in emerging economies, where affordability is a crucial factor in accessing molecular diagnostics.

The broader consequences of these manufacturing pressures are reflected in recent industrial performance metrics. According to the European Chemical Industry Council (Cefic), the chemical and biochemical manufacturing sector in Europe operated at a capacity utilization rate of approximately 75% in 2024, a figure significantly suppressed by high regulatory burdens and operational costs. This underutilization highlights the challenges manufacturers face in expanding output while managing compliance expenses. For the Proteinase K market, such financial and operational rigidities directly hamper the industry's capacity to meet the surging global demand for diagnostic testing materials.

Market Trends

The global market is experiencing a significant shift from native fungal extraction to recombinant production methods, spurred by the critical need for superior purity and batch consistency in biopharmaceutical applications. This transition addresses the stringent requirements of modern genomic workflows by providing enzymes that are free from animal-derived contaminants and possess higher specific activity than their natural counterparts. The industrial scale of this move toward advanced biomanufacturing inputs is substantial, supporting a supply chain capable of meeting elevated regulatory standards. As noted in Merck KGaA's 'Annual Report 2024' from March 2025, the company's Process Solutions business unit generated sales of €3.5 billion, a figure that underscores the robust demand for high-grade biological raw materials essential for producing such recombinant reagents.

Simultaneously, the widespread adoption of high-throughput automated workstations is driving a market preference for ready-to-use liquid formulations over traditional lyophilized powders. Laboratories are increasingly integrating automated liquid handling systems to eliminate manual pipetting errors and accelerate sample processing speeds, necessitating enzyme formats that are stable and immediately deployable in robotic workflows. This operational evolution is evidenced by the significant capital allocated to automation infrastructure by life sciences entities. According to Tecan Group's 'Annual Report 2024', released in March 2025, the company reported sales of CHF 397 million in its Life Sciences Business segment, highlighting the extensive deployment of the liquid handling platforms that drive the consumption of these specialized enzyme formulations.

Key Market Players

• Promega Corporation
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd
• Worthington Biochemical Corporation
• New England Biolabs, Inc.
• BIORON GmbH
• Sisco Research Laboratories Pvt. Ltd.
• Bioline Global Pty Ltd
• Codexis, Inc.

Report Scope

In this report, the Global Proteinase K Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Proteinase K Market, By Therapeutic Area

• Infectious Diseases
• Diabetes
• Oncology
• Cardiology
• Nephrology
• Autoimmune Diseases
• Neurology
• Others

Proteinase K Market, By Application

• Isolation & Purification Of Genomic DNA & RNA
• In Situ Hybridization
• Mitochondria Isolation
• Enzyme Removal

Proteinase K Market, By End User

• Contract Research Organization
• Academic Institutes
• Biotechnology Companies
• Diagnostic Laboratories

Proteinase K Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Proteinase K Market.

Available Customizations:

Global Proteinase K Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Proteinase K Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapeutic Area (Infectious Diseases, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune Diseases, Neurology, Others)
  • 5.2.2. By Application (Isolation & Purification Of Genomic DNA & RNA, In Situ Hybridization, Mitochondria Isolation, Enzyme Removal)
  • 5.2.3. By End User (Contract Research Organization, Academic Institutes, Biotechnology Companies, Diagnostic Laboratories)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Proteinase K Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapeutic Area
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Proteinase K Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapeutic Area
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Proteinase K Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapeutic Area
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Proteinase K Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapeutic Area
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Proteinase K Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapeutic Area
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Proteinase K Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapeutic Area
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Proteinase K Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapeutic Area
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Proteinase K Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapeutic Area
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Proteinase K Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapeutic Area
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Proteinase K Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapeutic Area
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Proteinase K Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapeutic Area
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Proteinase K Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapeutic Area
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Proteinase K Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapeutic Area
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Proteinase K Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapeutic Area
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Proteinase K Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapeutic Area
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Proteinase K Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapeutic Area
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Proteinase K Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapeutic Area
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Proteinase K Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapeutic Area
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Proteinase K Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapeutic Area
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Proteinase K Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapeutic Area
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Proteinase K Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapeutic Area
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Proteinase K Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapeutic Area
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Proteinase K Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapeutic Area
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Proteinase K Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapeutic Area
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Proteinase K Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Promega Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. QIAGEN N.V.
• 15.3. Thermo Fisher Scientific Inc.
• 15.4. F. Hoffmann-La Roche Ltd
• 15.5. Worthington Biochemical Corporation
• 15.6. New England Biolabs, Inc.
• 15.7. BIORON GmbH
• 15.8. Sisco Research Laboratories Pvt. Ltd.
• 15.9. Bioline Global Pty Ltd
• 15.10. Codexis, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer